Harm Reduction Therapeutics
  • Our Story
  • OTC RiVive®
  • Why 3 mg?
  • Contact Us
  • Login
  • My Account
  • Donate
  • Buy Now
  • What Is Harm Reduction
  • Resources
  • News
  • Events
  • FAQ
  • Partner Offerings
  • What Is Harm Reduction?
  • Resources
  • News
  • Events
  • FAQ
  • Partner Offerings
Open Society Supports an Innovative Model to Make Naloxone Easier to Access Amidst the U.S. Overdose Crisis

Open Society Supports an Innovative Model to Make Naloxone Easier to Access Amidst the U.S. Overdose Crisis

by C Tetro | Dec 12, 2023 | News

Partnership to Save Lives: Harm Reduction Therapeutics to donate 200,000 RiVive™ naloxone doses to Remedy Alliance for free distribution

Partnership to Save Lives: Harm Reduction Therapeutics to donate 200,000 RiVive™ naloxone doses to Remedy Alliance for free distribution

by C Tetro | Aug 17, 2023 | News

FDA APPROVAL OF RiVIVE™ IS A CRITICAL MILESTONE IN MAKING EMERGENCY TREATMENT OF OPIOID OVERDOSE MORE WIDELY AVAILABLE

FDA APPROVAL OF RiVIVE™ IS A CRITICAL MILESTONE IN MAKING EMERGENCY TREATMENT OF OPIOID OVERDOSE MORE WIDELY AVAILABLE

by C Tetro | Aug 1, 2023 | News

Comparison of Administration of 8-Milligram and 4-Milligram Intranasal Naloxone by Law Enforcement During Response to Suspected Opioid Overdose

Comparison of Administration of 8-Milligram and 4-Milligram Intranasal Naloxone by Law Enforcement During Response to Suspected Opioid Overdose

by C Tetro | Apr 11, 2023 | News

In 2021, an 8-mg intranasal naloxone product was approved by the Food and Drug Administration; however, no studies have examined outcomes among persons who receive the 8-mg naloxone product and those who receive the usual 4-mg product…
US FDA Has Model Drug  Facts Labels For OTC Naloxone, Needs Switch Proposals

US FDA Has Model Drug Facts Labels For OTC Naloxone, Needs Switch Proposals

by C Tetro | Nov 2, 2022 | News

« Older Entries
Next Entries »
  • Contact Us
  • Privacy Policy
  • Accessibility
  • FAQ
  • Follow
  • Follow
  • Follow
  • Follow

© Copyright 2025 Harm Reduction Therapeutics, Inc. All Rights Reserved. To report Adverse Events contact: customercare@harmreductiontherapeutics.org.